Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

PHSYX vs VGHCX overlap: 59% of top holdings shared

Bottom line

How much do PHSYX and VGHCX overlap?

59% of their top holdings overlap by weight. 14 securities appear in both funds' top 25, making up 63.1% of PHSYX's assets and 45.4% of VGHCX's. They share a meaningful core but differ in the rest of the portfolio.

Updated Nov 22, 2026

Overlap at a glance

PHSYXVGHCX
Weight overlap (top 25)59%
Shared holdings14
Weight in shared holdings63.1%45.4%
Total positions11597
Expense ratio0.79%0.33%
Holdings as ofMay 31, 2026Jul 31, 2026

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Holdings PHSYX and VGHCX have in common

Holding% of PHSYX% of VGHCXOverlap
Eli Lilly & Co.13.15%8.61%8.61%
Johnson & Johnson8.46%4.83%4.83%
UnitedHealth Group, Inc.6.93%4.05%4.05%
AbbVie, Inc.6.05%2.30%2.30%
Merck & Co., Inc.4.88%5.44%4.88%
AstraZeneca plc4.67%4.59%4.59%
Intuitive Surgical, Inc.4.04%2.52%2.52%
Edwards Lifesciences Corp.2.80%2.56%2.56%
Roche Holding AG2.79%1.18%1.18%
CVS Health Corp.2.74%2.52%2.52%
Vertex Pharmaceuticals, Inc.1.97%2.36%1.97%
Boston Scientific Corp.1.80%1.53%1.53%
Dexcom, Inc.1.64%1.18%1.18%
HCA Healthcare, Inc.1.18%1.68%1.18%

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in PHSYX

  1. Novartis AG — 5.13%
  2. Thermo Fisher Scientific, Inc. — 4.50%
  3. Sanofi SA — 3.23%
  4. Gilead Sciences, Inc. — 2.63%
  5. McKesson Corp. — 2.14%
  6. Cardinal Health, Inc. — 2.12%
  7. Novo Nordisk A/S — 1.90%
  8. Bristol-Myers Squibb Co. — 1.75%
  9. Hoya Corp. — 1.52%
  10. Putnam Short Term Investment Fund — 1.35%
  11. Amgen, Inc. — 1.11%

Only in VGHCX

  1. Gsk Plc — 3.00%
  2. Cencora Inc — 2.47%
  3. Danaher Corp — 2.18%
  4. Regeneron Pharmaceuticals Inc — 2.14%
  5. Novartis AG — 1.91%
  6. Elevance Health Inc — 1.83%
  7. Argenx SE — 1.68%
  8. Ucb Sa — 1.67%
  9. Agilent Technologies Inc — 1.49%
  10. Biogen Inc — 1.46%
  11. Galderma Group AG — 1.37%

Asset mix

Asset typePHSYXVGHCX
Stocks98.2%97.6%
Repurchase agreements—2.2%
Other1.4%—
Cash & short-term funds0.6%0.1%

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Country mix

CountryPHSYXVGHCX
US76.2%77.6%
CH7.9%4.5%
GB6.4%7.6%
JP2.4%4.8%
BE—3.4%
FR3.2%—
DK2.4%1.4%
NL1.2%—

Source: SEC Form N-PORT (periods May 31, 2026 / Jul 31, 2026)

Check another pair

FAQ

How much do PHSYX and VGHCX overlap?
About 59% by weight. 14 securities appear in both funds' top 25 holdings; they make up 63.1% of PHSYX's assets and 45.4% of VGHCX's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do PHSYX and VGHCX have in common?
The largest shared holdings are Eli Lilly & Co., Merck & Co., Inc., Johnson & Johnson, AstraZeneca plc, UnitedHealth Group, Inc..
Should I own both PHSYX and VGHCX?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, PHSYX or VGHCX?
PHSYX is broader, with 115 positions versus 97 for VGHCX. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.